If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solutionThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Ramucirumab: Approval for Treatment of NSCLC
In the US, ramucirumab, in combination with erlotinib, is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
US_cFAQ_RAM156_RELAY_APPROVAL
en-US
Detailed Information
On May 29, 2020, the FDA approved ramucirumab, in combination with erlotinib, for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.1
Enclosed Prescribing Information
Reference
1Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
EGFR = epidermal growth factor receptor
FDA = Food and Drug Administration
NSCLC = non-small cell lung cancer
Date of Last Review: May 29, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST